Burning Rock Announces Pricing of Initial Public Offering

NEXT STORY
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting
PREV STORY
CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ascendis Pharma A/S Announces Second Quarter 2018 Financial Results and Business Update Conference Call on August 29

COPENHAGEN, Denmark, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company ...

author_avatar
NASDAQ Market News

Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update

author_avatar
NASDAQ Market News

OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a ...

author_avatar
NASDAQ Market News